GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (MEX:RPRX) » Definitions » Total Debt per Share

Royalty Pharma (MEX:RPRX) Total Debt per Share : MXN366.17 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma Total Debt per Share?

MXN366.17 (As of Mar. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Royalty Pharma's Total Debt Per Share for the quarter that ended in Mar. 2025 was MXN366.17.

Royalty Pharma Total Debt per Share Historical Data

The historical data trend for Royalty Pharma's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Total Debt per Share Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Debt per Share
Get a 7-Day Free Trial 298.10 336.22 313.07 233.14 355.98

Royalty Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 225.93 310.13 335.83 355.98 366.17

Royalty Pharma Total Debt per Share Calculation

Royalty Pharma's Total Debt Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(137,953+20,809)/446
=355.98

Royalty Pharma's Total Debt Per Share for the quarter that ended in Mar. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(135,410+20,430)/426
=366.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (MEX:RPRX) » Definitions » Total Debt per Share
Comparable Companies
INSM BMRN INCY SMMT MRNA EXEL ASND TECH ROIV CORT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
RPRX:USA RPD:Germany
Address
110 East 59th Street, New York, NY, USA, 10022
Website
https://www.royaltypharma.com
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.